Boehringer Ingelheim has reported promising 14-week findings from the Phase II clinical trial of BI 690517 plus standard-of-care including empagliflozin in chronic kidney disease (CKD) patients.

The double-blind, placebo-controlled trial evaluated the safety and efficacy of varying oral doses of BI 690517 as monotherapy or on top of SGLT2 inhibitor empagliflozin.

It enrolled CKD patients who were receiving stable background therapy with an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme (ACE) inhibitor, irrespective of their type 2 diabetes status. 

According to the findings, the combination therapy offered up to a 39.5% decline in albuminuria, a kidney damage marker, compared to placebo.

Up to 70% of subjects in the BI 690517 plus empagliflozin arm attained a clinically meaningful decline in urine albumin creatinine ratio (UACR), a secondary endpoint. 

These reductions could translate into a decline in clinical kidney disease event risk by a minimum of 30%, the company noted.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the trial, BI 690517 was found to be well tolerated with no new safety signals reported. 

Developed by Boehringer, BI 690517 is a selective aldosterone synthase inhibitor (ASi).

Boehringer Ingelheim Human Pharma head Carinne Brouillon said: “These encouraging Phase II data not only demonstrate our commitment to developing innovative and transformational treatments for people living with cardio-renal-metabolic conditions but also have the potential to decrease the global burden of these interconnected diseases. 

“With over one billion people worldwide affected by these conditions, the potential to help reduce the pressure on healthcare systems and patients is immense.” 

The company anticipates commencing subject recruitment in the global Phase III EASi-KIDNEY trial of BI 690517 plus empagliflozin in established CKD patients.

In October this year, Boehringer and CDR-Life announced plans to launch a Phase I clinical trial of BI 771716 in preserving vision in geographic atrophy patients.